Background – Corneal Edema
The HyperCL
The Need
To date, medicine can hardly offer any help to suffering corneal edema patients, nor can it help prevent the condition itself or control most of its complications. Predominantly treatment consists of hyperosmotic eye-drops which are applied a few times a day. Obviously, the eye drops are cleared away very fast after a few eye blinks and therefore are of only minimal help.
Moreover, the eye drops commonly cause eye burns which may lead to low compliance. The long waiting lists (estimated 10M patients WW, 1/3 of which is attributed to corneal edema) for cornea transplants are yet another dreadful proof of the need for the HyperCL - an efficient and safe solution for the prevention and treatment of corneal edema.
Targeting corneal edema has two main aspects:
Up to 20% of eye operations which involve the cornea will result in short term corneal edema.
2. Treating chronic corneal edema patients: Estimated 1%-3% of patients with corneal edema will develop a chronic condition which will necessitate ongoing treatment.
Current Status
A PCT Patent Application entitled: “The Hyper Osmotic Contact Lens” has been submitted by Mor Research Applications in December 2008.
HyperCL is an innovative solution for an efficient non-invasive treatment of corneal edema. The clinical and economic advantages of the HyperCL result from prevention of post-operative complications, to include sparing the torment of costly recurring cornea transplantations. With an expected short time to market, the HyperCL is a true opportunity for real advancement in Ophthalmologic medicine, bringing a much anticipated solution to the huge corneal edema market.